The medication class known as proteasome inhibitors includes bortezomib. It functions by preventing the proteasomes, which are in charge of destroying proteins in cells, from functioning. Bortezomib inhibits this process, killing cancer cells by preventing their development and ability to survive.
1. The cancer multiple myeloma, which damages plasma cells in the bone marrow, is treated with bortezomib as a component of combination therapy.
2. Mantle Cell Lymphoma: This non-Hodgkin's lymphoma variant, which develops from B-cells, is also treated with it.
The intravenous (IV) injection of bortezomib is normally provided by medical experts at a hospital. Depending on the type and stage of the cancer as well as the unique characteristics of the patient, the dosage and treatment plan may change.
Bortezomib can have negative effects, much like most medicines. Low blood cell counts, exhaustion, nausea, vomiting, diarrhoea, and peripheral neuropathy (tingling or numbness in the hands and feet) are a few of the most typical adverse effects. During or soon after the medicine delivery, some individuals may also have infusion-related effects.
When taking bortezomib, patients must be continuously watched by their medical team in order to manage and treat any potential adverse effects.
The choice to utilise bortezomib as a cancer treatment should be decided by a licenced healthcare provider after taking into account the patient's individual medical history and current state. It's crucial to speak with a healthcare professional for thorough advice and direction if you or someone you know has been prescribed the medication Bortezomib for Injection or has questions about it.